NZ730490A - Methods and systems for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease - Google Patents

Methods and systems for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease Download PDF

Info

Publication number
NZ730490A
NZ730490A NZ730490A NZ73049015A NZ730490A NZ 730490 A NZ730490 A NZ 730490A NZ 730490 A NZ730490 A NZ 730490A NZ 73049015 A NZ73049015 A NZ 73049015A NZ 730490 A NZ730490 A NZ 730490A
Authority
NZ
New Zealand
Prior art keywords
ibs
antibodies
cdtb
vinculin
level
Prior art date
Application number
NZ730490A
Other languages
English (en)
Inventor
Christopher Chang
Mark Pimentel
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Publication of NZ730490A publication Critical patent/NZ730490A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/205—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Campylobacter (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ730490A 2014-10-09 2015-10-08 Methods and systems for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease NZ730490A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462061877P 2014-10-09 2014-10-09
US201462085825P 2014-12-01 2014-12-01
PCT/US2015/054655 WO2016057772A1 (en) 2014-10-09 2015-10-08 Methods and systems for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease

Publications (1)

Publication Number Publication Date
NZ730490A true NZ730490A (en) 2021-07-30

Family

ID=55653760

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ730490A NZ730490A (en) 2014-10-09 2015-10-08 Methods and systems for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease

Country Status (16)

Country Link
US (2) US10132814B2 (enExample)
EP (1) EP3204771B1 (enExample)
JP (1) JP6784669B2 (enExample)
KR (1) KR102426541B1 (enExample)
CN (1) CN107003308B (enExample)
AU (1) AU2015330872B2 (enExample)
CA (1) CA2962493C (enExample)
ES (1) ES3028294T3 (enExample)
IL (1) IL251606B (enExample)
MX (1) MX384921B (enExample)
NZ (1) NZ730490A (enExample)
PL (1) PL3204771T3 (enExample)
PT (1) PT3204771T (enExample)
RU (1) RU2706361C2 (enExample)
SG (1) SG11201702395WA (enExample)
WO (1) WO2016057772A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11693009B2 (en) 2009-02-11 2023-07-04 Cedars-Sinai Medical Center Methods for detecting post-infectious irritable bowel syndrome
US12222352B2 (en) 2017-01-30 2025-02-11 Cedars-Sinai Medical Center Diagnosis of scleroderma

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2656850T3 (es) 2009-02-11 2018-02-28 Cedars-Sinai Medical Center Diagnóstico del síndrome intestinal inflamatorio con base en la toxina de distensión citoletal
KR102203568B1 (ko) 2012-09-17 2021-01-15 세다르스-신나이 메디칼 센터 장 및 방광의 운동 장애 및 섬유근육통의 진단 및 치료
CN105744956B (zh) 2013-10-09 2021-07-20 西达-赛奈医疗中心 肠易激综合征和炎性肠病的诊断和治疗
EP3204771B1 (en) 2014-10-09 2025-03-12 Cedars-Sinai Medical Center Methods and systems for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease
EP3913371A1 (en) 2020-05-18 2021-11-24 Neuroimmun GmbH Method and kit for diagnosting irritable bowel syndrome and for its relief through dietary interventions
CN113447649B (zh) * 2021-07-01 2022-04-19 浙江大学 一种检测抗粘着斑蛋白-IgG抗体的试剂盒

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5691151A (en) 1994-10-07 1997-11-25 Regents Of University Of California Methods of screening for ulcerative colitis and crohn's disease by detecting VH3-15 autoantibody and panca
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6562629B1 (en) 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
FR2806805A1 (fr) 2000-03-22 2001-09-28 Centre Nat Rech Scient SEQUENCE PEPTIDIQUES COMPRENANT UN OU PLUSIEURS MOTIFS DE LIAISON AUX PROTEINES DE LA FAMILLE Ena/VASP, ET LEURS UTILISATIONS
AU2003233576A1 (en) 2002-05-17 2003-12-02 Sugen, Inc. Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals
AU2003291625B2 (en) 2002-09-16 2009-10-08 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US7595386B2 (en) 2003-01-24 2009-09-29 William Beaumont Hospital Methods and compositions for heat activated gene therapy using cytolethal distending toxin
MXPA05010819A (es) * 2003-04-08 2006-03-30 Progenics Pharm Inc Uso de antagonistas de opioide perifericos, especialmente metilnaltrexona para tratar sindrome de intestino irritable.
DE602004030586D1 (de) 2003-09-15 2011-01-27 Oklahoma Med Res Found Verfahren zur verwendung von cytokintests zur diagnose, behandlung und beurteilung von ankyloider spondylitis
KR101152078B1 (ko) 2003-12-05 2012-06-21 후소 야쿠힝 고교 가부시끼가이샤 세포팽창화 치사독 및 그것을 표적으로 한 캄필로박터속에속하는 세균의 검출
US20080085524A1 (en) 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
WO2008140484A2 (en) 2006-11-09 2008-11-20 Xdx, Inc. Methods for diagnosing and monitoring the status of systemic lupus erythematosus
US20110183337A1 (en) 2007-12-20 2011-07-28 Petra Von Stein Method and Kit for Use in the Differentiation of IBD and IBS and Further Distinction Between Disease Types of IBD
WO2010045180A1 (en) 2008-10-13 2010-04-22 Metabolon, Inc. Biomarkers for inflammatory bowel disease and methods using the same
ES2529060T3 (es) 2008-11-24 2015-02-16 Cedars-Sinai Medical Center Derivados antioxidantes de la camptotecina y nanoesferas antineoplásicas antioxidantes de los mismos
ES2656850T3 (es) 2009-02-11 2018-02-28 Cedars-Sinai Medical Center Diagnóstico del síndrome intestinal inflamatorio con base en la toxina de distensión citoletal
US20110294726A1 (en) 2009-02-11 2011-12-01 Cedars-Sinai Medical Center Antibiotic therapy to reduce the likelihood of developing post-infectious irritable bowel syndrome
FR2942541A1 (fr) 2009-02-25 2010-08-27 Assist Publ Hopitaux De Paris Procede de diagnostic d'une vascularite
RU2397178C1 (ru) * 2009-02-27 2010-08-20 Федеральное государственное учреждение науки "Центральный научно-исследовательский институт эпидемиологии" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека Диагностическая тест-система в формате иммуночипа и способ серологической дифференциальной диагностики сифилиса
IT1400989B1 (it) 2010-07-13 2013-07-05 Segix Italia S R L Ora Istituto Biochimico Naz Savio S R L Forme di somministrazione orale a rilascio controllato di rifampicina per il trattamento di infezioni batteriche dell' apparato intestinale.
GB201017520D0 (en) 2010-10-15 2010-12-01 Sense Proteomic Ltd Biomarkers
JP5477671B2 (ja) 2012-02-28 2014-04-23 三菱マテリアル株式会社 サーミスタ用金属窒化物材料及びその製造方法並びにフィルム型サーミスタセンサ
KR102203568B1 (ko) * 2012-09-17 2021-01-15 세다르스-신나이 메디칼 센터 장 및 방광의 운동 장애 및 섬유근육통의 진단 및 치료
CN105744956B (zh) 2013-10-09 2021-07-20 西达-赛奈医疗中心 肠易激综合征和炎性肠病的诊断和治疗
EP3204771B1 (en) 2014-10-09 2025-03-12 Cedars-Sinai Medical Center Methods and systems for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease
WO2018140869A1 (en) 2017-01-30 2018-08-02 Cedars-Sinai Medical Center Diagnosis of scleroderma

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11693009B2 (en) 2009-02-11 2023-07-04 Cedars-Sinai Medical Center Methods for detecting post-infectious irritable bowel syndrome
US12222352B2 (en) 2017-01-30 2025-02-11 Cedars-Sinai Medical Center Diagnosis of scleroderma

Also Published As

Publication number Publication date
US10690679B2 (en) 2020-06-23
RU2017115663A3 (enExample) 2019-05-16
IL251606A0 (en) 2017-06-29
EP3204771B1 (en) 2025-03-12
CN107003308A (zh) 2017-08-01
CA2962493C (en) 2023-01-10
AU2015330872A1 (en) 2017-04-13
WO2016057772A1 (en) 2016-04-14
EP3204771A1 (en) 2017-08-16
US20160103136A1 (en) 2016-04-14
PT3204771T (pt) 2025-05-20
KR102426541B1 (ko) 2022-07-29
CA2962493A1 (en) 2016-04-14
SG11201702395WA (en) 2017-04-27
CN107003308B (zh) 2020-02-11
IL251606B (en) 2020-08-31
MX2017004516A (es) 2017-10-12
RU2706361C2 (ru) 2019-11-18
EP3204771A4 (en) 2018-03-14
PL3204771T3 (pl) 2025-07-28
MX384921B (es) 2025-03-14
JP2017531801A (ja) 2017-10-26
KR20170067795A (ko) 2017-06-16
JP6784669B2 (ja) 2020-11-11
ES3028294T3 (en) 2025-06-18
AU2015330872B2 (en) 2021-04-22
RU2017115663A (ru) 2018-11-13
US20190187153A1 (en) 2019-06-20
US10132814B2 (en) 2018-11-20

Similar Documents

Publication Publication Date Title
US10690679B2 (en) Methods and systems for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease
AU2015205899B2 (en) Methods for diagnosing irritable bowel syndrome
KR102259588B1 (ko) 과민성 장 증후군 및 염증성 장 질환의 진단 및 치료
US12222352B2 (en) Diagnosis of scleroderma
US20240159772A1 (en) Methods for Detecting and Treating Irritable Bowel Syndrome
HK1234824B (en) Methods and systems for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease
HK1234824A1 (en) Methods and systems for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 OCT 2023 BY PAVIS PAYMENT GMBH

Effective date: 20221005

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 OCT 2024 BY BIRGIT KNAACK

Effective date: 20230929

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 OCT 2025 BY BIRGIT KNAACK

Effective date: 20240925

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 OCT 2026 BY CONSTANZE LINDHOFF

Effective date: 20251002